![Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20190401005452/en/712257/5/Ajovy_UK_Packshot_1pack-HiRes_highres.jpg)
Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Stock Price, Quote, News & History | Nasdaq
![Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Announces Abstracts at the ACAAI Annual Scientific Meeting Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Announces Abstracts at the ACAAI Annual Scientific Meeting](http://www.smarteranalyst.com/wp-content/uploads/2017/08/teva.png)